Welcome to our dedicated page for Benitec Biopharm news (Ticker: BNTC), a resource for investors and traders seeking the latest updates and insights on Benitec Biopharm stock.
Benitec Biopharma news coverage focuses on developments in the company's gene therapy programs, particularly its lead candidate BB-301 for Oculopharyngeal Muscular Dystrophy (OPMD). Media reporting frequently highlights clinical trial progress, including patient enrollment updates, interim data releases, and safety assessments from the ongoing Phase 1b/2a study. Regulatory milestones such as Orphan Drug Designations and Fast Track Designation from regulatory authorities represent significant news events that attract investor and industry attention.
Financial news related to Benitec Biopharma includes quarterly earnings reports, capital raising activities, stock performance, and analyst coverage. The company's funding announcements, which support ongoing clinical development and regulatory activities, are closely monitored by the investment community. News outlets report on the company's cash position, operational runway, and strategic plans for advancing BB-301 toward potential regulatory submissions and commercial development.
Scientific conference presentations and peer-reviewed publications provide additional news coverage opportunities for Benitec Biopharma. The company presents data from its clinical programs at medical and scientific conferences focused on muscular dystrophy, rare diseases, and gene therapy. These presentations offer insights into the therapeutic potential of ddRNAi technology and the clinical profile of BB-301. Industry publications covering the broader gene therapy and biotechnology sectors frequently discuss Benitec Biopharma's technological approach and competitive positioning within the genetic medicine landscape.
Investor relations activities, including conference participation, webcasts, and corporate updates, generate news coverage that keeps stakeholders informed about company developments. Announcements regarding clinical trial design modifications, expansion into additional patient cohorts, and preparation for potential pivotal studies are among the key news topics. The company's progress toward addressing an orphan disease with no approved treatments creates sustained media interest from both healthcare and financial news sources. Developments in the broader gene therapy industry, regulatory policy changes affecting orphan drug development, and advancements in RNA interference technologies also influence news coverage of Benitec Biopharma and its therapeutic programs.
Benitec Biopharma Inc. (NASDAQ: BNTC) announced that a Late Breaking Abstract on BB-301 has been accepted for oral presentation at the 29th Annual Congress of the World Muscle Society in Prague, Czech Republic, from October 8-12, 2024. The presentation, scheduled for October 12, 2024, will focus on interim clinical data from a Phase 1b/2a study evaluating the safety and clinical activity of BB-301, an AAV9-based gene therapy for Oculopharyngeal Muscular Dystrophy (OPMD) with dysphagia. Professor Milan R. Amin, M.D., from the New York University Grossman School of Medicine, will present the findings. This presentation represents a significant milestone in Benitec's development of novel genetic medicines using their proprietary 'Silence and Replace' DNA-directed RNA interference (ddRNAi) platform.
Benitec Biopharma (NASDAQ: BNTC) announced that CEO Jerel A. Banks, M.D., Ph.D., will participate in the Oculopharyngeal Muscular Dystrophy (OPMD) Awareness Day Webinar on September 23, 2024, at 12 PM EST. The event, organized by the OPMD Association, aims to raise awareness about OPMD, a rare, genetic, adult-onset, progressive myopathy.
Dr. Banks will provide an update on the BB-301 Phase 1b/2a clinical development program. The webinar will offer patients, families, and caregivers clinical insights, patient perspectives, and informational resources to support understanding and care for OPMD. Benitec Biopharma is a clinical-stage biotechnology company developing novel genetic medicines based on its proprietary 'Silence and Replace' DNA-directed RNA interference (ddRNAi) platform.
Benitec Biopharma (NASDAQ: BNTC) reports continued improvements in swallowing efficiency for the first OPMD subject treated with low-dose BB-301 in their Phase 1b/2a study. At the 180-day post-dose assessment, Total Pharyngeal Residue (TPR) remained meaningfully reduced compared to pre-dose values. For three of four food types, TPR values were lower than at any point during the 9-month pre-dose observation period.
The Sydney Swallow Questionnaire (SSQ) Total Score showed continued reductions in dysphagic symptoms, indicating improved swallowing function. Both TPR and SSQ scores are considered central markers for evaluating clinical improvement in OPMD patients. The company plans to dose the third subject in Q3 2024 and report additional interim results in Q1 2025.
Benitec Biopharma, a clinical-stage gene therapy-focused biotechnology company, has appointed Kishen Mehta to its board of directors, effective June 26, 2024. This follows a $40 million PIPE financing led by Suvretta Capital, where Mehta is a portfolio manager. CEO Jerel A. Banks emphasized Mehta's expertise in investing, corporate development, and strategy, particularly as the company advances its Phase 1b/2a study for BB-301, a treatment for Oculopharyngeal Muscular Dystrophy (OPMD). Mehta brings over 15 years of financial industry experience, including roles at Biohaven Pharmaceuticals, Surveyor Capital, and Adage Capital, with a focus on healthcare investments. He expressed enthusiasm for contributing to Benitec's mission to develop effective treatments for OPMD patients.
Benitec Biopharma reported positive interim clinical trial data for the first Oculopharyngeal Muscular Dystrophy (OPMD) subject dosed with BB-301, with improvements noted in swallowing assessments. The company closed an oversubscribed $40.0 million private financing round extending cash runway through 2025. Operational updates include enrollment of 23 subjects in the OPMD Natural History Study and milestones related to BB-301 development.
Benitec Biopharma Inc. (BNTC) will participate in the Citizens JMP Life Science Conference in New York on May 13-14, 2024, presenting its gene therapy-focused ddRNAi platform. The presentation by Jerel Banks, MD, PhD, Executive Chairman and CEO, will be webcasted live.
FAQ
What is the current stock price of Benitec Biopharm (BNTC)?
What is the market cap of Benitec Biopharm (BNTC)?
